News – Page 1102 – Endpoints News

Eli Lilly gets a short cut at FDA for abemaciclib; Calyxt files for $100M IPO

8 years ago

Alnylam, Sanofi flag another promising step forward for PhIII hemophilia drug

8 years ago

FDA raises big safety issues in Novartis’ CAR-T review, but spotlights post-marketing path forward

8 years ago

Celgene vet Jackie Fouse grabs the reins of a Vivek Ramaswamy vant-up

8 years ago

After a quick trial revamp, FDA lifts its clinical hold on Concert’s hair-loss drug

8 years ago

Inotek shares crater (again) as another glaucoma drug study flops

8 years ago

Shire blasts Roche over its 'misleading' case for trailblazing hemophilia drug emicizumab, scoring injunction

8 years ago

Emmaus who? A biotech you never heard of just won an historic drug OK for sickle cell disease

8 years ago

Feds' case spotlights Shkreli’s disastrous biotech short -- which forced him to launch Retrophin

8 years ago

Ex-Alexion CEO Hallal named chairman at Scholar Rock; Advaxis CEO O'Connor is out

8 years ago

Upstart women’s oncology company in-licenses PhII PARP; Beijing biotech grabs $29M startup round

8 years ago

Zealand Pharma blueprints an $86M IPO on Nasdaq as it maneuvers its way into PhIII

8 years ago

Sanofi and Alnylam plunge into PhIII with a rival to Roche’s top hemophilia drug

8 years ago

J&J turns its back on Capricor and its failed stem cell tech, taking its money and rep with it

8 years ago

Dogged by accusations of shady sales practices, Alexion finds itself under investigation by HHS -- Bloomberg

8 years ago

Novartis turns to Oxford BioMedica for a major CAR-T supply deal

8 years ago

Novartis backs a $13M round for Anaeropharma; Eli Lilly investing $52M in pharma research program with Purdue

8 years ago

Google’s data-crunching mavens at GV buy in to Decibel’s R&D program for hearing loss, tinnitus

8 years ago

Medicxi’s new fund jumps off the beaten biotech path to lead a $30M round for diabetes program

8 years ago

Celgene joins the PD-1 checkpoint club, bagging BeiGene drug with $413M down and $1B on the table

8 years ago

Troubled by deaths, FDA orders Merck to slam the brakes on three Keytruda studies

8 years ago

Personalized cancer vaccines stake their claim to the next frontier in immuno-oncology

8 years ago

Court papers outline an angry showdown between Pascal Soriot and a departing Luke Miels

8 years ago

Endpoints Insider: The world’s oldest new biotech pub ends its 12th month on a roll

8 years ago

First page Previous page 1099 1100 110111021103 1104 1105 Next page Last page